AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Rhea-AI Summary

AIM ImmunoTech (NYSE:AIM) updated terms of its previously announced rights offering and reminded stockholders that the subscription period expires March 3, 2026 at 5:00 p.m. ET. Each subscription right now purchases one Unit for $1,000, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G common warrants.

Each Preferred share is convertible into 1,000 common shares (conversion price $1.00). Each warrant is exercisable for one common share at $1.00 per share and expires five years after issuance. Rights are non-transferable and exercise is irrevocable. The offering is made under an effective Form S-1 declared effective Feb. 10, 2026.

Positive

• Immediate capital access via $1,000 per Unit subscriptions
• Long-dated warrants exercisable for five years at $1.00 per share

Negative

• Potential dilution from conversion of 1,000 shares plus 2,000 warrants per Unit
• Non-transferable, irrevocable subscription rights once exercised
• Short window to subscribe: expires March 3, 2026 at 5:00 p.m. ET

Key Figures

Rights subscription price: $1,000 per Unit Preferred conversion ratio: 1,000 common shares per preferred share Warrants per Unit: 2,000 Class G Warrants +5 more

8 metrics

Rights subscription price $1,000 per Unit Updated rights offering terms in Feb 27, 2026 press release

Preferred conversion ratio 1,000 common shares per preferred share Series G Convertible Preferred Stock under updated rights terms

Warrants per Unit 2,000 Class G Warrants Each Unit in updated rights offering

Conversion price $1.00 per share Conversion price for Series G Preferred Stock

Warrant exercise price $1.00 per share Exercise price for Class G Warrants

Rights expiration time 5:00 p.m. ET on March 3, 2026 Deadline to exercise subscription rights

Units registered 12,000 Units 424B3 prospectus for rights offering

Shelf capacity $100 million Form S-3/A shelf registration aggregate amount

Market Reality Check

Price: $0.9900 Vol: Volume 221,955 is at 0.06...

low vol

$0.9900 Last Close

Volume Volume 221,955 is at 0.06x the 20-day average, indicating subdued pre-news activity. low

Technical Shares at $0.99 are trading below the $2.67 200-day moving average and 95.13% under the 52-week high.

Peers on Argus

AIM fell 2.94% while peers showed mixed moves: TNFA down 9.72%, PMCB down 2.94%,...

1 Up 2 Down

AIM fell 2.94% while peers showed mixed moves: TNFA down 9.72%, PMCB down 2.94%, but BCLI, HCWB and NCNA up between 1.39% and 15.83%. This points to a stock-specific reaction to the rights offering terms rather than a clean sector-wide move.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Rights offering extension	Neutral	-4.7%	Extended subscription period for ongoing rights offering to March 3, 2026.
Feb 23	Clinical milestones	Positive	+2.9%	Outlined Phase 2 DURIPANC enrollment, dosing, and endpoint timelines for Ampligen combo.
Feb 12	Rights offering terms	Neutral	+58.2%	Commencement of rights offering for up to 12,000 Units at $1,000 per Unit.
Feb 12	Investor event	Neutral	-6.4%	Announcement of live virtual investor Closing Bell event focused on Ampligen and DURIPANC.
Feb 11	Rights offering launch	Neutral	-13.5%	Launch of rights offering targeting $12M gross proceeds via preferred and warrant Units.

Pattern Detected

Recent financing-related announcements have triggered sizeable but directionally mixed moves, while clinical milestones drew a modest positive reaction.

Recent Company History

Over the past weeks, AIM has focused on capital raising and its Ampligen program. Multiple rights-offering announcements since Feb 11, 2026 outlined up to 12,000 Units at $1,000 each, with changing warrant and conversion terms, and have produced both sharp gains and selloffs. In parallel, a Phase 2 DURIPANC trial update on Feb 23, 2026 highlighting planned milestones and timelines drew a modest 2.86% gain, underscoring investor attention to clinical progress alongside dilution risk.

Regulatory & Risk Context

Active S-3 Shelf · $100 million

Shelf Active

Active S-3 Shelf Registration 2025-06-27

$100 million registered capacity

AIM has an effective Form S-3/A shelf registration filed on June 27, 2025, authorizing up to $100 million of securities across multiple instruments. The shelf has been used in conjunction with recent offerings, including the rights-offering prospectus supplements on Feb 17, 2026 and Feb 27, 2026, indicating active use of this capital-raising capacity.

Market Pulse Summary

This announcement updates terms and deadlines for AIM’s rights offering, clarifying a structure of $...

Analysis

This announcement updates terms and deadlines for AIM’s rights offering, clarifying a structure of $1,000 Units, each with convertible preferred stock and 2,000 warrants at a $1.00 exercise price, expiring March 3, 2026. Recent prospectus supplements and an effective $100 million shelf underscore an active capital-raising strategy. Investors may monitor subscription levels, subsequent use of proceeds, and how this funding supports Ampligen’s development milestones in metastatic pancreatic cancer.

Key Terms

rights offering, convertible preferred stock, warrants, subscription rights, +4 more

8 terms

rights offering financial

"announced updated terms for its previously announced rights offering (the “Rights Offering”)."

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

convertible preferred stock financial

"one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”)"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

warrants financial

"2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”)"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

subscription rights financial

"Each subscription right now entitles holders to purchase one unit (the “Units”)"

Subscription rights are short-term privileges given to existing shareholders to buy additional new shares before the general public, typically at a set price and in proportion to their current holdings. Think of it as getting a coupon for first dibs on extra slices of a pizza so your share of the pie doesn’t shrink; exercising them can be a cheaper way to maintain your ownership and voting power, while ignoring them can reduce your stake and potential future earnings.

over-subscription privilege financial

"subscription price for both basic subscription rights and any over-subscription privilege election"

An over-subscription privilege is a feature of a share offering that lets existing investors request more shares than their initial entitlement, with any extra allocation given only if other investors do not take their full allotment. It matters because it gives shareholders a chance to increase their stake and avoid losing ownership percentage, much like ordering extra slices at a party in case others pass—however, receiving the extras is not guaranteed.

dealer-manager financial

"The Company has engaged Maxim Group LLC as dealer-manager for the Rights Offering."

A dealer-manager is the lead broker or firm that organizes and runs a securities offering, coordinating other dealers, setting up the sale, marketing the issue to investors, and handling order allocation and settlement. Think of it as the project manager for a new issue: its effectiveness affects how widely the offering is distributed, the fees charged, and how smoothly investors can buy or sell the securities, so investors watch the dealer-manager for potential conflicts, pricing quality, and execution reliability.

registration statement on Form S-1 regulatory

"pursuant to the Company’s registration statement on Form S-1 (File No. 333-292085)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The Rights Offering is being made only by means of a prospectus, copies of which have been delivered"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”).

Each subscription right now entitles holders to purchase one unit (the “Units”), each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”) at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 1,000 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the conversion price ($1.00 per share). Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.00 per share from the date of issuance through its expiration five years from the date of issuance.

All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any over-subscription privilege election, to the Subscription Agent, to be received before 5:00 p.m. Eastern Time on March 3, 2026. The address of the Subscription Agent is:

Broadridge, Inc.
Attn: BCIS IWS
51 Mercedes Way
Edgewood, NY 11717

The subscription rights are non-transferable and will only be exercisable during the subscription period. Once holders have exercised their subscription rights, such exercise may not be revoked, canceled, or changed, even if holders subsequently learn information about the Company or its business, financial position, results of operations or cash flows that is material or adverse or that the holders otherwise consider to be unfavorable. The Company may cancel, modify or amend the rights offering at any time and for any reason prior to the expiration of the subscription period. Subscription rights which are not exercised by the expiration date of the Rights Offering will expire and will have no value.

The Company has engaged Maxim Group LLC as dealer-manager for the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention Syndicate Department, or via e-mail at syndicate@maximgrp.com or telephone at +1 (212) 895-3745.

The Rights Offering is being made pursuant to the Company’s registration statement on Form S-1 (File No. 333-292085) (as amended, the “Registration Statement”), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2026. The Rights Offering is being made only by means of a prospectus, copies of which have been delivered to holders of the Company's Common Stock as of 5:00 p.m., Eastern Time, on the Record Date and can be accessed through the SEC’s website at www.sec.gov. Questions about the Rights Offering or requests for a copy of the prospectus related to the Rights Offering may be directed to the Information Agent, Broadridge Corporate Issuer Solutions, LLC, at (855) 793-5068 or via e-mail at shareholder@broadridge.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any subscription rights, Common Stock, Warrants, Units or any other securities, nor will there be any offer, solicitation or sale of any subscription rights, Common Stock, Warrants, Units or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction. This press release is not an offering and an offering can only be made by the prospectus and any prospectus supplements for the Rights Offering, which should be read carefully before making an investment decision.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

IR Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

When does AIM (NYSE:AIM) rights offering expire and what is the deadline to subscribe?

The rights offering expires on March 3, 2026 at 5:00 p.m. ET. According to the company, holders must deliver a completed rights certificate and payment to the Subscription Agent to be received by that deadline.

What does one Unit cost in the AIM rights offering and what does it include?

Each Unit costs $1,000 and includes one Series G Convertible Preferred share plus 2,000 Class G common warrants. According to the company, the subscription price is $1,000 per Unit.

How many common shares does AIM Series G Preferred convert into under the rights offering?

Each Preferred share converts into 1,000 common shares at the holder's option. According to the company, conversion equals the stated value ($1,000) divided by the $1.00 conversion price.

What are the AIM warrant terms included in the Units (exercise price and expiration)?

Each Warrant is exercisable for one common share at $1.00 per share and expires five years from issuance. According to the company, each Unit includes 2,000 such warrants.

How can AIM stockholders exercise rights and who is the Subscription Agent?

Stockholders must deliver a completed rights certificate plus payment to the Subscription Agent, Broadridge, to be received by the deadline. According to the company, Broadridge Corporate Issuer Solutions is the Subscription Agent handling subscriptions.